BioCheck Acquires IVD Company DRG International

BioCheck Inc. (San Francisco, CA, USA) has acquired DRG International Inc. (Springfield, NJ, USA), a manufacturer of clinical diagnostic and research ELISAs with distributors in over 110 countries.

DRG is also the manufacturer of the DRG:HYBRiD-XL, a fully automated analyzer for Immunoassays and Clinical Chemistry. DRG International, Inc. operates in accordance with the FDA 21 CFR 820 Quality System Regulation as well as the ISO 13485:2016 and MDSAP (Medical Device Single Audit Program) by TÜV Rheinland. BioCheck has been engaged in the development and manufacturing of high-quality in vitro diagnostic test kits for the worldwide biomedical, pharmaceutical, and scientific research markets under cGMP and ISO 13485 standards. BioCheck is commercializing the (automated chemiluminescent platform (ACL-Platform) and associated COVID-19 and other cytokine, metabolic, and cardiovascular test kits to allow convenient, instant, and accurate diagnosis of disease markers with a bench top instrument.


“The DRG:HYBRiD-XL and BioCheck's new automated chemiluminescent platform (ACL-Platform) will enable us to accelerate the availability of optimized, reliable and accurate advanced clinical and research diagnostic tests in the neurological disorders and other diseases,” said Roy Paxton Yih, CEO of BioCheck, Inc. “Leveraging BioCheck's assay development capabilities with DRG's development center, the combined companies are well positioned to rapidly scale availability of current tests and develop novel IVD tests for several diseases in the future globally to over 110 countries.”

Related Links:
BioCheck Inc.